Meduslabs — Evidence-based health research
HomeCancerPancreatic Cancer: Symptoms, Causes, Stages, Treatment, and Immune Support
Key Takeaways

What is pancreatic cancer?

Pancreatic cancer is a tumour found in any part of the pancreas. Cancer begins when cells start to multiply uncontrollably. Pancreatic adenocarcinoma is the most common type. The pancreas produces hormones and enzymes that help digest food and, among other functions, regulate blood sugar levels.

Pancreatic cancer — anatomy and immune response

Symptoms

Pancreatic cancer often shows no symptoms until it reaches a later stage — so there are no reliable early signs. The most common symptoms of established cancer are:

As the cancer spreads, symptoms become more pronounced and new ones may appear.

Did I inherit it?

Only up to 1 in 10 pancreatic cancer cases may be inherited. The other 90% are acquired — mutations that happen during life, not inherited ones. These DNA mutations are not passed from parents to children.1

Why do we get it?

Causes within your control:

Stages

Once pancreatic cancer is found, further tests assess how far it has spread. Based on the results, the oncologist assigns a stage:

Life expectancy with pancreatic cancer depends heavily on spread, the treatment chosen, and the patient's condition.

Treatment

Treatment and survival depend on the stage. The goal is to destroy cancer cells and prevent the disease from spreading. The most common complications during treatment are weight loss, constipation, abdominal pain and liver failure.

Surgery: the stage and location determine whether surgery is performed. Surgery can remove the primary tumour, but it will not remove cancer that has spread elsewhere — so it may be unsuitable for people with advanced-stage pancreatic cancer. Radiotherapy: when the cancer has spread beyond the pancreas, radiotherapy may be prescribed, using X-rays and other radiation to destroy cancer cells. Chemotherapy: in some cases the oncologist may combine chemotherapy with other treatments.

What else can I do in the fight against pancreatic cancer?

If you want to help your body heal, reduce inflammation, balance your diet and strengthen the immune system's ability to recognise and destroy altered cells, relying on chemotherapy, surgery or radiotherapy alone will not be enough (though do not avoid them — with prevention you are already late). You will help yourself considerably by doing the following:

Related supplement

Pancreatic cancer is hard to catch early. Concentrated mushroom polysaccharides are studied for their role in supporting NK-cell and macrophage activity alongside conventional treatment.

Lentinan AXT by Zenius Labs™ →
What are the symptoms of pancreatic cancer?

Pancreatic cancer often causes no symptoms until a later stage, so there are no reliable early signs. Common symptoms of established disease include loss of appetite, weight loss, abdominal or back pain, blood clots, jaundice (yellowing of the eyes), and depression.

Is pancreatic cancer hereditary?

Only up to 1 in 10 cases may be inherited. The other 90% are acquired — DNA mutations that happen during life and are not passed from parents to children.

Can you support the immune system during pancreatic cancer?

Yes. Chemotherapy and radiotherapy suppress the immune system. Concentrated mushroom-polysaccharide extracts are studied for their role in helping activate natural killer cells and macrophages. It is important to choose a concentrated multi-extract formula such as Lentinan AXT by Zenius Labs™ rather than simple powders.

What are the main risk factors for pancreatic cancer?

Factors within your control include sugar and sweetened drinks, smoking, alcohol, excess weight, pesticides, environmental chemicals and cadmium. Genetics accounts for only about 10% of cases.

References
  1. Heavy Drinking Linked to Pancreatic Cancer. WebMD
  2. Environment and Health Research Newsletter. European Commission
  3. Common Chemicals Linked to Pancreatic Cancer. WebMD
  4. Risk of pancreatic cancer and occupational exposures in Spain. Cancer Epidemiology
  5. Capula M et al. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2022. PubMed
  1. Kim G nab-Paclitaxel for the treatment of pancreatic cancer. Cancer management and research. 2017. PubMed
  2. Zhang Y et al. Immune Therapy in Pancreatic Cancer: Now and the Future?. Reviews on recent clinical trials. 2015. PubMed
  3. Das S et al. Harnessing the Immune System in Pancreatic Cancer. Current treatment options in oncology. 2018. PubMed
  4. Carpenter ES et al. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cancer research. 2020. PubMed
  5. Tang M et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?. Journal of controlled release : official journal of the Controlled Release Society. 2019. PubMed
  6. Zheng R et al. Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy. Oncology reports. 2026. PubMed
  7. Jiang S et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. Journal of experimental & clinical cancer research : CR. 2023. PubMed
  8. Goetze TO et al. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of surgical oncology. 2024. PubMed
  9. Byrne JD et al. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer chemotherapy and pharmacology. 2018. PubMed
  10. Nywening TM et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology. 2016. PubMed
  11. Tran NH et al. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. International journal of radiation oncology, biology, physics. 2020. PubMed
  12. Lee JH et al. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia. Cells. 2021. PubMed
  13. Zhang Y et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. International immunopharmacology. 2008. PubMed
  14. Yu X et al. Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia. Nutrition and cancer. 2024. PubMed
  15. Bossi P et al. The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021. PubMed
  16. Luo L et al. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano today. 2024. PubMed
  17. Mortezaee K Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. Journal of biochemical and molecular toxicology. 2021. PubMed
  18. Liu X et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science translational medicine. 2024. PubMed
  19. Datta J et al. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer. Gastroenterology. 2022. PubMed
  20. Lin HJ et al. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma. Cancers. 2023. PubMed
  21. Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
  22. Liu Y et al. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Cell death and differentiation. 2025. PubMed
  23. Zhou J et al. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Cancer letters. 2023. PubMed
  24. Deng Y et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature communications. 2021. PubMed
  25. Zhou W et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021. PubMed
  26. Mukherji R et al. The Role of Immunotherapy in Pancreatic Cancer. Current oncology (Toronto, Ont.). 2022. PubMed
  27. Feng M et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer letters. 2017. PubMed
  28. Jolly G et al. Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic. Cancers. 2023. PubMed
  29. Bangolo AI et al. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights. World journal of gastroenterology. 2023. PubMed
  30. Halle-Smith JM et al. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?. Cancers. 2023. PubMed
  31. Li P et al. Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives. Cancer letters. 2024. PubMed
  32. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  33. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  34. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  35. Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
  36. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  37. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  38. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  39. Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
  40. Sun M et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surgical oncology. 2015. PubMed
  41. Zhang P et al. A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer. International journal of nanomedicine. 2018. PubMed
  42. Shimizu K et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-gastroenterology. 2009. PubMed
  43. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  44. Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
  45. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  46. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  47. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
  48. Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
  49. Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
  50. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  51. Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed
Zenius Labs™

Lentinan AXT — advanced mushroom-polysaccharide formula

Lentinan AXT by Zenius Labs™ combines Lentinus edodes and Coriolus versicolor polysaccharides with astaxanthin in a concentrated, precision formula — every active ingredient selected on the basis of published research into NK-cell and macrophage activity alongside oncological treatment.

Get Lentinan AXT